Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations

被引：2
|
作者：
不详
机构：
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2022.10.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E3 / E4
页数：2
相关论文
共 50 条
  • [21] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [22] Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.
    Riess, Jonathan
    Floch, Nicolas
    Martin, Matthew
    Orme, Jonathon
    Staniszewska, Anna
    Menard, Ludovic
    Cuomo, Maria Emanuela
    O'Neill, Daniel
    Ward, Richard
    Finlay, Raymond
    McKerrecher, Darren
    Cheng, Mingshan
    Tang, Daniel
    Tsai, Rebekah
    Ye, Chunting
    Keck, James G.
    Gandara, David R.
    Mack, Philip C.
    Cross, Darren
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Osimertinib (AZD9291) is effective against NSCLC cells harboring EGFR exon 20 insertion mutations
    Lee, Yusoo
    Kim, Tae Min
    Kim, Dong-Wan
    Ahn, Yong-Oon
    Kim, Soyeon
    Keam, Bhumsuk
    Kim, Miso
    Heo, Dae Seog
    CANCER RESEARCH, 2017, 77
  • [24] Final Overall Survival Analysis of Osimertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations (KCSG-LU15-09)
    Cho, J. H.
    Lim, S. H.
    An, H. J.
    Kim, K. H.
    Park, K. U.
    Kang, E. J.
    Choi, Y. H.
    Ahn, M. S.
    Sun, J. -M.
    Lee, S. -H.
    Ahn, J. S.
    Park, K.
    Ahn, M. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S145 - S145
  • [25] Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation
    Cardona, Andres F.
    Jaramillo-Velasquez, Daniel
    Ruiz-Patino, Alejandro
    Polo, Carolina
    Jimenez, Enrique
    Hakim, Fernando
    Gomez, Diego
    Fernando Ramon, Juan
    Cifuentes, Hernando
    Armando Mejia, Juan
    Salguero, Fernando
    Ordonez, Camila
    Munoz, Alvaro
    Bermudez, Sonia
    Useche, Nicolas
    Pineda, Diego
    Ricaurte, Luisa
    Lucia Zatarain-Barron, Zyanya
    Rodriguez, July
    Avila, Jenny
    Rojas, Leonardo
    Jaller, Elvira
    Sotelo, Carolina
    Garcia-Robledo, Juan Esteban
    Santoyo, Nicolas
    Rolfo, Christian
    Rosell, Rafael
    Arrieta, Oscar
    JOURNAL OF NEURO-ONCOLOGY, 2021, 154 (03) : 353 - 364
  • [26] Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation
    Andrés F. Cardona
    Daniel Jaramillo-Velásquez
    Alejandro Ruiz-Patiño
    Carolina Polo
    Enrique Jiménez
    Fernando Hakim
    Diego Gómez
    Juan Fernando Ramón
    Hernando Cifuentes
    Juan Armando Mejía
    Fernando Salguero
    Camila Ordoñez
    Álvaro Muñoz
    Sonia Bermúdez
    Nicolas Useche
    Diego Pineda
    Luisa Ricaurte
    Zyanya Lucia Zatarain-Barrón
    July Rodríguez
    Jenny Avila
    Leonardo Rojas
    Elvira Jaller
    Carolina Sotelo
    Juan Esteban Garcia-Robledo
    Nicolas Santoyo
    Christian Rolfo
    Rafael Rosell
    Oscar Arrieta
    Journal of Neuro-Oncology, 2021, 154 : 353 - 364
  • [27] NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
    Maemondo, M.
    Fukuhara, T.
    Sugawara, S.
    Takiguchi, Y.
    Inoue, A.
    Oizumi, S.
    Ishii, Y.
    Yoshizawa, H.
    Isobe, T.
    Gemma, A.
    Morita, S.
    Hagiwara, K.
    Kobayashi, K.
    Nukiwa, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.
    Furuya, Naoki
    Fukuhara, Tatsuro
    Saito, Haruhiro
    Watanabe, Kana
    Sugawara, Shunichi
    Iwasawa, Shunichiro
    Tsunezuka, Yoshio
    Yamaguchi, Ou
    Okada, Morihito
    Yoshimori, Kouzou
    Nakachi, Ichiro
    Gemma, Akihiko
    Azuma, Koichi
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    Morita, Satoshi
    Kobayashi, Kunihiko
    Maemondo, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study
    Okuma, Yusuke
    Kubota, Kaoru
    Shimokawa, Mototsugu
    Hashimoto, Kana
    Kawashima, Yosuke
    Sakamoto, Tomohiro
    Wakui, Hiroshi
    Murakami, Shuji
    Okishio, Kyoichi
    Hayashihara, Kenji
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
    Lee, Yusoo
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Soyeon
    Kim, Miso
    Keam, Bhumsuk
    Ku, Ja-Lok
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1556 - 1566
12345